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ABSTRACT
Objective Low-grade intestinal inﬂammation plays a
role in the pathophysiology of IBS. In this trial, we aimed
at evaluating the efﬁcacy and safety of mesalazine in
patients with IBS.
Design We conducted a phase 3, multicentre, tertiary
setting, randomised, double-blind, placebo-controlled trial
in patients with Rome III conﬁrmed IBS. Patients were
randomly assigned to either mesalazine, 800 mg, or
placebo, three times daily for 12 weeks, and were
followed for additional 12 weeks. The primary efﬁcacy
endpoint was satisfactory relief of abdominal pain/
discomfort for at least half of the weeks of the treatment
period. The key secondary endpoint was satisfactory relief
of overall IBS symptoms. Supportive analyses were also
performed classifying as responders patients with a
percentage of afﬁrmative answers of at least 75% or
>75% of time.
Results A total of 185 patients with IBS were enrolled
from 21 centres. For the primary endpoint, the responder
patients were 68.6% in the mesalazine group versus
67.4% in the placebo group (p=0.870; 95% CI −12.8 to
15.1). In explorative analyses, with the 75% rule or
>75% rule, the percentage of responders was greater in
the mesalazine group with a difference over placebo of
11.6% (p=0.115; 95% CI −2.7% to 26.0%) and 5.9%
(p=0.404; 95% CI −7.8% to 19.4%), respectively,
although these differences were not signiﬁcant. For the
key secondary endpoint, overall symptoms improved in the
mesalazine group and reached a signiﬁcant difference of
15.1% versus placebo (p=0.032; 95% CI 1.5% to
28.7%) with the >75% rule.
Conclusions Mesalazine treatment was not superior
than placebo on the study primary endpoint. However, a
subgroup of patients with IBS showed a sustained therapy
response and beneﬁts from a mesalazine therapy.
Trial registration number ClincialTrials.gov number,
NCT00626288.
INTRODUCTION
IBS is the most common functional GI disorder in
which abdominal pain and/or discomfort is asso-
ciated with changes in bowel habit, and with features
of disordered defecation. IBS affects 10–20% of the
population and causes a marked reduction of quality
of life in affected individuals.1 IBS is a heterogeneous
disorder involving a combination of negative life
experiences and trauma, particularly early in life,
genetic predisposition and environmental factors.
Patients with IBS show dysfunction in the brain–gut
axis, including anxiety, depression, gut dysmotility
and visceral hypersensitivity. The relative importance
of central versus peripheral mechanism in the IBS
pathophysiology remains poorly deﬁned.2 Mounting
evidence is showing microscopic and molecular
abnormalities in large subsets of patients with IBS.3
The most compelling evidence linking inﬂammation
to IBS is the demonstration of the development of
IBS in 3.7–36.8% of subjects following acute infec-
tious gastroenteritis.4 5 Mucosal and systemic
immune activation have also been widely documen-
ted in patients with IBS in the absence of a previous
major gastroenteritis event.3 Mucosal inﬂammation
is linked to increased mucosal permeability,6
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Signiﬁcance of this study
What is already known on this subject?
▸ A high proportion of patients with IBS show
low-grade inﬂammation in the intestinal mucosa.
▸ Low-grade inﬂammation is likely to be
multifactorial, involving genetic factors, stress,
atopy, previous episodes of infectious
gastroenteritis, changes in gut microbiota and
epithelial barrier defects.
▸ A previous proof-of-concept trial showed that
mesalazine reduced the number of total
immune cells and mast cells in the colonic
mucosa of patients with IBS.
What are the new ﬁndings?
▸ This is the ﬁrst large randomised controlled
trial assessing the efﬁcacy and safety of
mesalazine in IBS.
▸ Mesalazine did not improve the percentage of
patients with satisfactory relief of abdominal
pain/discomfort for at least half of the weeks of
the treatment period.
▸ Mesalazine signiﬁcantly improved the
percentage of patients with satisfactory relief of
overall IBS symptoms if sustained responses
were required (>75% of treatment period).
How might it impact on clinical practice in
the foreseeable future?
▸ A subgroup of patients with IBS showed a
sustained therapy response and beneﬁts from
mesalazine therapy.
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enterochromafﬁn cell hyperplasia and higher tissue availability of
serotonin, a key factor involved in the control of gut sensorimotor
functions.7 8 Another key ﬁnding linking inﬂammation to IBS
pathophysiology and symptom generation is the observation that
adoptive transfer of mucosal biopsy supernatants evoked activation
of sensory pain pathways9 10 and abnormal enteric nervous system
responses in recipient rodents.11–13 Interestingly, these responses
were reduced to a large extent by antagonism of immune-related
factors including proteases and histamine.9 10 12 13 The origin of
low-grade inﬂammation in patients with IBS remains undeter-
mined, but it is likely to be multifactorial, involving genetic predis-
position,14 15 stress,16 atopy,17 abnormal intestinal microbiota18
and higher mucosal permeability increasing antigenic exposure of
the mucosa to luminal antigens.6
Taken together, the above-reported evidences provide the
rationale to test the efﬁcacy of intestinal anti-inﬂammatory com-
pounds in patients with IBS. In a previous randomised, placebo-
controlled proof-of-concept trial, we showed that compared
with placebo, mesalazine reduced the number of total immune
cells, T cells and mast cells in the colonic mucosa of patients
with IBS.19 Although this trial was underpowered to detect
effects on symptoms, a promising improvement on the patient’s
general well-being was identiﬁed.19 In addition, while cortico-
steroid treatment was ineffective in symptom improvement at
least in 29 patients with postinfectious IBS,20 mast cell stabili-
sers, such as cromolyn sodium21 and ketotifen,22 showed prom-
ising results particularly in IBS with diarrhoea, suggesting a role
of immune mechanisms and mast cells in IBS symptom gener-
ation. However, well-designed controlled studies are needed to
conﬁrm the efﬁcacy of these drugs in IBS. Finally, mesalazine is
the therapy of ﬁrst choice for the treatment (clinical improve-
ment, not necessarily remission) and maintenance of clinical
remission in patients with mild-to-moderate UC.23
In the present study, we assessed the clinical efﬁcacy and
safety of mesalazine against placebo in a large, phase 3, rando-
mised, double-blind, placebo-controlled, multicentre study in
patients with IBS.
METHODS
Study design
This is a phase III, randomised, double-blind, placebo-
controlled, parallel-arm, multicentre trial designed to study the
efﬁcacy and safety of mesalazine in adult patients with IBS. The
study included a 2-week screening period, a 12-week placebo-
controlled treatment period and a 12-week follow-up period
(ﬁgure 1). After the screening phase, eligible patients were ran-
domly assigned to either mesalazine 800 mg three times daily or
placebo in a 1:1 ratio. All the subjects were blindly allocated by
means of scratch cards to one of the two treatment groups
(mesalazine or placebo) according to a computer-generated ran-
domisation list provided by the sponsor. A validated SAS
program was used by an independent statistician to generate a
randomisation list with blocks, block size=4, preallocated to
centres. All patients, study investigators and sponsor staff were
blinded to the randomisation codes. The codes were kept conﬁ-
dential until the end of the study when the randomisation code
was broken after the database lock. Study visits were conducted
every two weeks during the treatment period and every four
weeks during the follow-up period.
The protocol was designed by the coordinating centre (GB,
CC, RC and VS). Data were collected by investigators at each of
the 21 Italian test centres and were monitored by the sponsor
with the supervision of On Pharmaceutical Industry Service
(OPIS) (a contract research organisation). OPIS personnel, in
collaboration with the coordinating centre, analysed the trial
data. A statistical analysis plan (SAP) was released and approved
by the sponsor prior to the database lock and the unblinding of
the treatment.
Study patients
Eligible patients with symptoms meeting Rome III criteria for
diagnosis of IBS1 were recruited in the study from a total of 21
Italian centres. Inclusion and exclusion criteria are reported in
online supplementary ﬁle.
Study assessment
Visits took place at screening, at baseline (randomisation visit)
and every two weeks during the treatment period. During the
follow-up, visits occurred monthly. The study data collection
was carried out through a paper clinical case report form.
Patients recorded daily all symptoms in a paper patient diary.
Use of concomitant medication and adverse events were
recorded at each visit. Additional safety data, such as haematol-
ogy, blood chemistry and vital signs, were monitored.
The primary endpoint was assessed using a binary scale based
on the patient answers to the following weekly question: “Did
you have satisfactory relief of your abdominal discomfort or
pain during the last week?” The patients were classiﬁed as
responders if they reported an afﬁrmative answer in at least
50% of weeks over a 3-month treatment period (50% rule).
Explorative analyses were also performed. Patients were classi-
ﬁed as responders if they reported a percentage of afﬁrmative
answers for at least 75% or >75% of the treatment time (75%
rule and >75% rule, respectively). The 75% rule was pre-
planned, as documented in the SAP, while the >75% rule was
post hoc and performed with the intention of minimising
placebo effect and optimising drug–placebo differences.
The key secondary endpoint was assessed using a binary scale
based on the patient answers to the following weekly question:
“Did you have satisfactory relief of your overall IBS symptoms
during the last week?” The patients were classiﬁed as responders
if they reported an afﬁrmative answer in at least 50% of weeks
over a 3-month treatment period. Explorative analyses were also
performed. Patients were classiﬁed as responders if they reported
a percentage of afﬁrmative answers for at least 75% or >75% of
the treatment time (75% rule and >75% rule, respectively).
The other secondary endpoints included daily assessment of
abdominal pain or discomfort, bloating and general well-being,
monitored using a 10-point visual analogue scale, and daily
assessment of stool frequency and consistency (by means of the
Bristol Stool Scale Form). At the end of the treatment period,
Figure 1 Study design. There was a screening period of 2 weeks
before randomisation (1:1), a 12-week placebo-controlled treatment
period and a 12-week follow-up period. Study visits occurred every
two weeks during treatment period and every four weeks during
follow-up.
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patients were asked to assess their overall satisfaction with treat-
ment using a 10-point visual analogue scale. Weekly number of
rescue medications was also computed. In addition, patients
completed the IBS-speciﬁc quality of life questionnaire
(IBS-QoL)24 and the short-form 36 items health survey
(SF-36)25 at baseline, at the end of the treatment period and at
the end of follow-up.
Statistical analysis
Based on our previous proof-of-concept study,19 we estimated
the sample size for the study assuming that 30% of the patients
in the placebo group and 55% in the mesalazine group would
meet the criteria for the primary endpoint, namely the percent-
age of responder patients. A sample of 136 patients (68 patients
in each of the two treatment group) was needed to have 80%
power to show the 25-percentage-point difference between the
groups at a signiﬁcance level of 0.05. Assuming a dropout rate
of 23% (36/159), the sample size was adjusted to 178 patients
according to Freedman’s formula.
All subjects who took at least one dose of the study treat-
ments were included in the safety population. All randomised
patients who took at least one dose of the study drug and with
at least one evaluation of the primary endpoint were included in
the intention-to-treat (ITT) population. All randomised patients
who completed the entire treatment period without any major
deviation from the protocol procedures were included in the
per protocol (PP) population.
The primary efﬁcacy population was ITT. The analysis on PP
population was performed for supportive data. The results of the
two analyses were evaluated for consistency. The percentage of
responder patients was calculated by treatment group, and the
difference between the percentages was tested by means of a χ2
test. In order to evaluate the effect of treatment over time, a
logistic model for repeated measures was applied. Dropout
patients were handled in the following way: if the reason for dis-
continuation was the inefﬁcacy of the therapy, patients were con-
sidered as non-responders; for all other reasons, in case of early
discontinuation, a prevalence approach was adopted. In this
approach, incomplete data were ignored. To illustrate the robust-
ness of the conclusions, a sensitivity analysis was performed. The
best scenario and the worst scenario were assumed for patients
with missing values. In the ﬁrst case, missing values were replaced
with afﬁrmative answers, in the latter with negative answers. The
analysis was also performed adopting the complete case
approach, considering only patients without missing data. Results
were compared for consistency and if they led to similar conclu-
sions there was reasonable assurance that the loss of information
had no effect on the overall study conclusions. The Cochran–
Mantel–Haenszel test was applied to test the difference in pro-
portion between treatment groups, adjusting for site and for IBS
type. The Breslow–Day test was applied in order to evaluate the
homogeneity in the OR among sites and IBS types.
All the secondary efﬁcacy analyses were performed on the
ITT population. For the key secondary endpoint, that is, the
percentage of patients with satisfactory relief of overall IBS
symptoms, the same approach adopted for the primary endpoint
was applied. To evaluate the difference between treatments in
the overall satisfaction with treatment at the end of the treat-
ment period, the unpaired t test or the Mann–Whitney test was
applied, according to the data distribution. To evaluate the dif-
ference between treatments in abdominal pain/discomfort, bloat-
ing and general well-being intensity, the analysis of covariance
(ANCOVA) model for repeated measures was applied consider-
ing values at week 2 and at week 1, treatment week and the
interaction treatment week as effect. Normality was assessed by
means of the Shapiro–Wilk test. In case of non-normality of
data, a rank transformation was applied. Stool frequency and
consistency was described by treatment group and by day.
Summary descriptive statistics of weekly stool frequency were
provided by treatment group and by week. The weekly number
of rescue medications was computed and described with
summary statistics by treatment group and by week. IBS-QoL
and SF-36 questionnaire data recorded at baseline, at the end of
treatment and at the end of follow-up were described by treat-
ment. The difference in answer distribution between treatments
was tested by means of a Cochran–Armitage test for trend
(exact version in case of cell numerousness lower than 5). No
correction for multiple comparisons was applied due to the
exploratory nature of this analysis. To evaluate the difference
between treatments in total score and subscores, the ANCOVA
model for repeated measures was applied considering value at
baseline, treatment, time point and interaction treatment–time
point as effect.
All statistical tests were performed with a signiﬁcance level of
α=0.05. The data were analysed by means of the SAS System
for Windows V.9.2.
RESULTS
Study patients
The ﬂow chart of the enrolment and randomisation of the study
is reported in ﬁgure 2. The study was conducted from February
2008 through March 2012. A total of 185 patients with IBS
were included in the study. Among the enrolled patients, ﬁve
were not randomised and were excluded from all analyses. In
total, 180 patients were randomised, 88 allocated to mesalazine
and 92 to placebo treatment groups. One patient randomised to
the placebo group did not take at least one dose of the study
treatment. Thus, the safety population consisted of 179 patients.
Seven other patients were excluded from the ITT population as
they did not have any evaluation of the primary endpoint. Thus,
172 subjects received at least one dose of the study drug and
were included in the ITT population. Among the 180 rando-
mised patients, 50 patients prematurely discontinued the treat-
ment. The primary reason included consent withdrawal
(17 patients), adverse events (14 patients), lost during follow-up
(8 patients), protocol violation (6 patients) and other reasons
(5 patients). Protocol violations are reported in the online sup-
plementary ﬁle. Overall, 85.5% of patients in the safety popula-
tion took the study treatments, with compliance between 70%
and 120%. Demographic and baseline characteristics of the
safety population were similar between treatment groups and
are reported in table 1.
Primary efﬁcacy analysis
Satisfactory relief of abdominal discomfort or pain
The logistic model for repeated measures did not reveal a statis-
tically signiﬁcant effect for treatment (p=0.324), nor inter-
action between treatment and time (p=0.897). The answers
varied signiﬁcantly with time (p<0.001). Using the same model
to test the simple main effect, no statistical signiﬁcance was
detected at any week of treatment, although a borderline effect
(p=0.060) resulted for week 8 (ﬁgure 3A).
According to the prevalence approach, responder patients
were 68.6% in the mesalazine group versus 67.4% in the placebo
group, with a δ difference in favour of the mesalazine group of
1.2% (p=0.870; 95% CI −12.8% to 15.1%) (ﬁgure 3B).
Non-statistically signiﬁcant results were conﬁrmed in the PP
population, in which responder patients were 75.0% in the
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mesalazine group versus 76.2% in the placebo group (p=0.878;
difference=−1.2%; 95% CI −16.4% to 14.0%). Among patients
without missing data, responder patients were 79.1% in the
mesalazine group versus 78.3% in the placebo group (p=0.904;
difference=0.8%; 95% CI −12.9% to 14.6%). In the ‘worst
scenario’ and ‘best scenario’, the results were similar, indicating
that missing data had no impact on the main result. The
Breslow–Day test showed no homogeneity differences in the OR
among sites (p=0.464) and IBS subtypes (ie, IBS with constipa-
tion (IBS-C), IBS with diarrhoea (IBS-D), mixed IBS (IBS-M);
p=0.193). The percentage of responder patients according IBS
subtypes is reported in the online supplementary ﬁle.
Explorative analysis
Figure 3B shows the supportive analysis performed considering
patients as responders if they reported a percentage of afﬁrma-
tive answers in at least 75% or >75% of the 3 months of treat-
ment, adopting a prevalence approach. With the 75% rule,
responder patients were 43.0% in the mesalazine group versus
31.4% in the placebo group, with a δ difference of 11.6%
(p=0.115; 95% CI −2.7% to 26.0%). With the >75% rule,
responder patients were 32.6% in the mesalazine group versus
26.7% of patients in the placebo group, with a δ difference of
5.9% (p=0.404; 95% CI −7.8% to 19.4%).
Considering treatment and follow-up period together, no sig-
niﬁcant differences in the responder rate were observed between
the mesalazine and placebo groups (67.4% vs 61.6%, respect-
ively; p=0.426; difference=5.8%; 95% CI −8.46% to 20.09%).
Secondary efﬁcacy analysis
Satisfactory relief of overall IBS symptoms
The logistic model for repeated measures did not reveal statistic-
ally signiﬁcant effects for treatment (p=0.155), nor interaction
between treatment and time (p=0.640). The answers varied sig-
niﬁcantly with time (p=0.004). Using the same model to test
the simple main effect, a borderline signiﬁcant effect was
Figure 2 Flow chart of enrolment and randomisation of the study. A total of 185 patients with IBS were included in the study. Of these, ﬁve were not
randomised and were excluded from all analyses. Of the 180 patients randomised, 88 were allocated to mesalazine and 92 to placebo. One patient
randomised to placebo did not take at least one dose of the study treatment. Seven other patients were excluded from the intention-to-treat (ITT)
population as they did not have any evaluation of the primary endpoint. Thus, 172 subjects were included in the ITT population. PP, per protocol.
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detected at week 3 (p=0.060) and a statistical signiﬁcance was
detected at week 5 (p=0.038) (ﬁgure 4A).
According to the prevalence approach, responder patients
were 66.3% in the mesalazine group versus 61.6% in the placebo
group, with a δ in favour of the mesalazine group of 4.7%
(p=0.525; 95% CI −9.7% to 19.0%) (ﬁgure 4B). Among
patients without missing data, responder patients were 73.1% in
the mesalazine group versus 71.0% in the placebo group
(p=0.783; difference=2.2%; 95% CI −13.0% to 17.2%).
Similar data were obtained with both the ‘worst scenario’ and
‘best scenario’, indicating that missing data had no impact on the
results. The Cochran–Mantel–Haenszel detected no statistically
signiﬁcant difference in proportion between treatment groups
adjusted for site (p=0.513). The percentage of responder
patients according to IBS subtypes is reported in the online
supplementary ﬁle.
Explorative analysis
Figure 4B shows the supportive analysis adopting a prevalence
approach. With the 75% rule, 46.5% of patients in the mesala-
zine group were responders versus 34.9% in the placebo group,
with a δ difference of 11.6% (p=0.121; 95% CI −3.0% to
26.2%). With the >75% rule, 38.4% of patients were responders
in the mesalazine group versus 23.3% in the placebo group, with
a δ difference of 15.1% (p=0.032; 95% CI 1.5% to 28.7%).
Considering treatment and the follow-up period together, no
signiﬁcant differences in the responder rate were observed
between the mesalazine and placebo groups (69.8% vs 59.3%,
respectively; p=0.151; difference=10.5%; 95% CI −3.8% to
24.7%). With the 75% rule, 41.9% of patients were responders
in the mesalazine group versus 29.1% in the placebo group.
The difference was 12.8% and borderline signiﬁcant (p=0.080;
difference=12.8%; 95% CI −1.4% to 27.0%).
Abdominal pain/discomfort, bloating and stool characteristics
Table 2 reports descriptive statistics by treatment group and by
week for abdominal pain/discomfort and bloating. The
ANCOVA model for repeated measures applied to the changes
versus values at week 2 did not detect a statistically signiﬁcant
difference between treatment groups for all the aforementioned
analyses (abdominal pain/discomfort: p=0.903; bloating:
p=0.184). No relevant difference between treatment groups
was detected for stool consistency and stool frequency (see
online supplementary ﬁle).
General well-being, IBS-QoL, SF-36 and satisfaction with
treatment
Table 2 reports descriptive statistics by treatment group and by
week for general well-being, IBS-QoL and SF-36.
The ANCOVA model for repeated measures applied to the
changes versus baseline at the end of treatment and at the end
of follow-up, applied to general well-being, IBS-QoL and SF-36
data, did not show statistically signiﬁcant difference between
treatments.
IBS-QoL scores were characterised by high variability. Except
from the sexual score that remained unchanged, all other items
at the end of follow-up versus baseline showed higher values in
the mesalazine group than in the placebo group, although there
Table 1 Baseline characteristics of study participants
Characteristics
Placebo
(n=91)
Mesalazine
(n=88) p Value
Age, years (±SD) 40.3 (12.2) 41.0 (11.6) 0.556
Female gender, n (%) 54 (59.3) 51 (58.0) 0.851
Ethnic origin 0.613
Caucasian, n (%) 89 (97.8) 85 (96.6)
African, n (%) 1 (1.1) 2 (2.3)
Asian, n (%) 1 (1.1) 0
Other, n (%) 0 (0) 1 (1.1)
IBS subtype (3) 0.481
IBS-D, n (%) 39 (42.8) 30 (34.1)
IBS-C, n (%) 18 (19.8) 18 (20.4)
IBS-M, n (%) 34 (37.4) 40 (45.5)
Abdominal pain score*† (±SD) 4.5 (2.3) 4.6 (2.5) 0.930
Bloating score*† (±SD) 5.0 (2.7) 5.4 (2.8) 0.377
IBS-QoL† (±SD) 65.2 (16.4) 62.9 (17.4) 0.439
General well-being*† (±SD) 4.1 (2.5) 4.8 (2.5) 0.074
SF-36† (±SD) 65.1 (15.4) 62.7 (16.0) 0.324
Data are reported as number of patients (%) or mean±SD.
*These parameters were collected at the screening visit (week 2).
†Results are reported on intention-to-treat population.
QoL, quality of life; SF-36, short-form 36 items health survey.
Figure 3 Primary efﬁcacy analysis (satisfactory relief of abdominal
pain or discomfort). The logistic model for repeated measures did not
reveal a statistically signiﬁcant effect for treatment (p=0.324) nor
interaction between treatment and time (p=0.897). The answers varied
signiﬁcantly with time (p<0.001). Using the same model to test the
simple main effect, a borderline signiﬁcant effect (p=0.060) resulted
for week 8 (A). According to the prevalence approach, responder
patients were 68.6% in the mesalazine group versus 67.4% in the
placebo group, with a δ difference in favour of the mesalazine group of
1.2% (p=0.870; 95% CI −12.8% to 15.1%) (B). Explorative analyses.
With the 75% rule, 43.0% of patients in the mesalazine group were
responders versus 31.4% in the placebo group, with a δ difference of
11.6% (p=0.115; 95% CI −2.7% to 26.0%) (B). With the >75% rule,
32.6% of responder patients were identiﬁed in the mesalazine group
versus 26.7% of patients in the placebo group, with a δ difference of
5.9% (p=0.404; 95% CI −7.8% to 19.4%) (B).
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were no signiﬁcant differences between the two groups (data
not shown).
SF-36 scores were characterised by high variability. Except
from the role limitations due to emotional problems score, the
vitality score, the social functioning score and the global mental
score, all other items at the end of follow-up versus baseline
showed higher values in the mesalazine group than in the
placebo group, although there were no signiﬁcant differences
between the two groups (data not shown).
The average overall satisfaction with treatment was 6.4±2.5
in the mesalazine group and 5.8±2.7 in the placebo group
(p=0.266).
Rescue medication
In the placebo group, the average frequency of rescue medica-
tion was higher than that of the mesalazine group in most of the
weeks of observation, but the differences were not statistically
signiﬁcant. In the ANCOVA model for repeated measures on the
weekly rescue medication frequencies, neither treatment effect
(p=0.482) nor interaction treatment week effect (p=0.492)
was signiﬁcant.
Safety
The safety proﬁle of mesalazine was similar to that of placebo
(table 3). Serious treatment emergent adverse events (ie, occur-
ring after the ﬁrst study medication exposure) were reported in
four patients in the mesalazine group versus zero patients in the
placebo groups and included two cases of gastroenteritis, one
case of ischaemic colitis and one case of relapse of breast cancer.
No deaths occurred during the study.
DISCUSSION
This multicentre controlled trial assessed the efﬁcacy and safety
of mesalazine in the treatment of patients with IBS. The percent-
age of patients giving afﬁrmative answers to the weekly question
on satisfactory relief of abdominal pain or discomfort for >50%
of the treatment period was set as the primary endpoint of the
study. With this cut-off value, compared with placebo, mesalazine
did not increase the percentage of responders.
There are several reasons explaining why we chose as primary
endpoint the satisfactory relief of abdominal pain or discomfort
for at least 50% of weeks over a 3-month treatment period.
First, adequate or satisfactory relief of abdominal pain or overall
IBS symptoms were the standards for primary outcome assess-
ment in IBS trials at the time of the study design.26 Responders
were considered to be those patients who reported adequate or
satisfactory relief in at least 50% of weeks over the treatment
period.27 28 These binary endpoints were used in several trials
in IBS.27 29 Abdominal pain is the key symptom of IBS and cor-
relates with the severity of disease30 and the use of healthcare
resources.31 Second, in our previous proof-of-concept study
assessing the effect of mesalazine on intestinal immune cells, we
observed a promising effect of mesalazine on abdominal pain.19
The new Food and Drug Administration and European
Medicines Agency recommended end points substantially differ-
ent from the past,32 making the comparison between old and
new studies complex. Based on previous studies showing a
similar degree of immune cell activation both in patients with
IBS-D and IBS-C,33 we hypothesised that mesalazine could be
effective in the reduction of abdominal pain in all subgroups of
patients with IBS. In line with this hypothesis, we did not show
any signiﬁcant difference in treatment responses based on bowel
habits.
One of the possible explanations for the lack of effect of
mesalazine using the 50% cut-off value could be the high
placebo response seen in this trial, which likely masked drug
efﬁcacy. The high number of planned visits, a short run-in
period, the selection of patients from tertiary centres and the
type of primary endpoint chosen could have all played a role in
the high placebo response recorded in the present study,34 and
generally, in the high level of responders. Furthermore, the
enrolment of both male and female subjects and patients with
mild symptoms, due to the lack of a minimum requirement for
the severity of abdominal discomfort/pain or duration of disease
in the inclusion criteria, may have contributed to the high
placebo response. Another limitation of the study is related to
the small sample size. Data indicating that mesalazine had posi-
tive effects but did not reach a statistical signiﬁcant suggest a
type 2 error. Our sample size calculation may have been limited
by lack of data from previous placebo-controlled trials assessing
the efﬁcacy of mesalazine in IBS, with the exception of our pre-
vious proof-of-concept study.19
Figure 4 Secondary efﬁcacy analysis (satisfactory relief of the overall
IBS symptoms). The logistic model for repeated measures did not reveal
statistically signiﬁcant effect for treatment (p=0.155) nor interaction
between treatment and time (p=0.640). The answers varied
signiﬁcantly with time (p=0.004). Using the same model to test the
simple main effect, a borderline signiﬁcant effect was detected at week
3 (p=0.060) and a statistical signiﬁcance was detected at week 5
(p=0.038) (A). According to the prevalence approach, responder
patients were 66.3% in the mesalazine group versus 61.6% in the
placebo group, with a δ in favour of the mesalazine group of 4.7%
(p=0.525; 95% CI −9.7% to 19.0%) (B). Explorative analyses. With the
75% rule, 46.5% of patients in the mesalazine group were responders
versus 34.9% in the placebo group, with a δ difference of 11.6%
(p=0.121; 95% CI −3.0% to 26.2%) (B). With the >75% rule, 38.4%
of responder patients were identiﬁed in the mesalazine group versus
23.3% of patients in the placebo group, with a δ difference of 15.4%
(p=0.032; 95% CI 1.5% to 28.7%) (B).
Barbara G, et al. Gut 2016;65:82–90. doi:10.1136/gutjnl-2014-308188 87
Neurogastroenterology
group.bmj.com on July 19, 2016 - Published by http://gut.bmj.com/Downloaded from 
By increasing the percentage of time required to deﬁne the
responders (75 and >75% rule), we found markedly higher
response rates in the mesalazine group compared with the
placebo group. This effect was evident in the satisfactory relief
of abdominal pain as well as in the overall IBS symptom end-
points. In particular, a statistically signiﬁcant improvement in
the satisfactory relief of the overall IBS symptoms was found
with the >75% rule. The δ difference over placebo was >15%,
and the number needed to treat was 7. The >75% rule is a
more restrictive outcome measure and selects a smaller
percentage of responders. These data indicate that a subgroup
of patients with IBS responded better to mesalazine than
placebo. These more restrictive outcome measures have been
previously used in the tegaserod28 and linaclotide35 trials and
help to distinguish the ‘sustained’ responders to the active treat-
ment from those responding to placebo. In line with this obser-
vation, in two randomised trials on linaclotide for chronic
constipation, only 5% of subjects who received placebo was
considered responders due to the rigour of the primary end-
point.35 However, due to the explorative nature of these ana-
lyses, further studies are needed to conﬁrm these results.
In addition to improving overall IBS symptoms with the 75%
rule, mesalazine improved the percentage of responders to pain
and discomfort at week 8 (50% rule) and the percentage respon-
ders to overall symptoms at weeks 3 and 5 (50% rule). There was
also a trend in a better improvement of pain intensity and bloat-
ing as well as quality of life and a lower requirement of rescue
medications with mesalazine, although these data did not reach
statistical signiﬁcance.
Although a subgroup of patients was more responsive to the
mesalazine treatment, our data did not allow to identify these
subjects. Patients with low-grade mucosal inﬂammation are pos-
sible candidates for a good response. In previous studies, we
showed that low-grade intestinal inﬂammation is present roughly
in half of the IBS population.33 36 However, in the present study,
we did not preselect these patients as the requirement of invasive
techniques would have signiﬁcantly reduced the enrolment rate.
Similar percentages of patients in the mesalazine group and in
the placebo group had adverse events. In addition, the favour-
able safety proﬁle of mesalazine was demonstrated in long-term
Table 3 Treatment-emergent adverse events during the study
Event Placebo (n=91) Mesalazine (n=88)
Adverse events
Upper respiratory tract infections 7 (7.7%) 11 (12.5%)
Diarrhoea 10 (11.0%) 6 (6.8%)
Headache 8 (8.8%) 5 (5.7%)
Nausea 2 (2.2%) 4 (4.6%)
Flatulence 4 (4.4%) 3 (3.4%)
Vomiting 3 (3.3%) 2 (2.3%)
Dyspepsia 4 (4.4%) 0 (0%)
Serious adverse events
Gastroenteritis 0 (0%) 2 (2.3%)
Ischaemic colitis 0 (0%) 1 (1.1%)
Breast cancer 0 (0%) 1 (1.1%)
Adverse events are listed in descending order of frequency in the mesalazine group.
The adverse events listed were reported in 2% or more of the patients in either
treatment group.
Table 2 Descriptive statistics by treatment group and by week for abdominal pain/discomfort, bloating, general well-being, IBS-QoL and SF-36
Mesalazine (n=86) Placebo (n=86) p Value
Abdominal pain/discomfort intensity
Mean (SD) Baseline (week 2) 4.59 (2.54) 4.50 (2.34)
Mean change versus baseline (SD) End of treatment −1.07 (2.54) −1.21 (2.36)
End of follow-up −1.07 (2.63) −0.85 (2.94)
Least squares means (SE)*** 1384.18 (63.80) 1394.80 (58.80) 0.903*
Bloating intensity
Mean (SD) Baseline (week 2) 5.37 (2.77) 4.97 (2.65)
Mean change versus baseline (SD) End of treatment −1.30 (2.63) −0.88 (2.54)
End of follow-up −0.93 (2.35) −1.25 (3.15)
Least squares means (SE)*** 1305.12 (62.41) 1418.13 (57.06) 0.184*
General well-being
Mean (SD) Baseline (week 2) 4.75 (2.45) 4.11 (2.50)
Mean change versus baseline (SD) End of treatment 0.53 (2.50) 1.31 (2.84)
End of follow-up 0.39 (2.68) 1.43 (3.87)
Least squares means (SE)*** 1283.61 (61.55) 1314.83 (57.24) 0.712*
IBS-QoL total score
Mean (SD) Baseline 62.93 (17.36) 65.16 (16.41)
Mean change versus baseline (SD) End of treatment 7.06 (12.89) 5.81 (11.60)
End of follow-up 9.34 (13.28) 6.52 (14.30)
Least squares means (SE)* 7.89 (1.41) 6.12 (1.40) 0.374**
SF-36 total score
Mean (SD) Baseline 62.68 (16.01) 65.09 (15.38)
Mean change versus baseline (SD) End of treatment 5.78 (12.90) 5.74 (13.44)
End of follow-up 8.17 (14.27) 7.60 (15.63)
Least squares means (SE)** 125.98 (7.37) 125.19 (7.35) 0.940***
*Least squares means and p value from an ANCOVA model for repeated measures on ranks of change versus baseline, considering as effects treatment, visit and interaction visit–
treatment and as covariate value at week 1, value at week 2.
**Least squares means and p value from an ANCOVA model for repeated measures on original values/on ranks.
***Of change versus baseline, considering as effects treatment, visit and interaction visit–treatment and as covariate value at baseline.
QoL, quality of life; SF-36, short-form 36 items health survey.
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studies in the maintenance of remission of UC.37 Although the
study showed no major adverse events in the mesalazine group
as compared with placebo, long-term and larger studies are
needed to assess this issue in patients with IBS.
In conclusion, the results of the present study indicate that a
number of patients show a sustained therapy response and bene-
ﬁts from mesalazine therapy. Larger studies assessing the clinical
predictors and conﬁrming the beneﬁcial effects of mesalazine
are now required.
Author afﬁliations
1Department of Medical and Surgical Sciences, Centre for Applied Biomedical
Research, University of Bologna, Bologna, Italy
2Division of Gastroenterology SOD2, University Hospital Careggi, Florence, Italy
3Gastroenterology Unit, Ospedale Maggiore, Policlinico, Milan, Italy
4Gastroenterology Unit, Department of Medical and Surgical Sciences, University of
Bologna, Bologna, Italy
5Gastroenterology Unit, Department of Gastroenterology, University of Pisa, Pisa,
Italy
6Department of Gastroenterology and Hepatology, Università Politecnica delle
Marche, Ancona, Italy
7Gastroenterology Unit, University of Verona, Verona, Italy
8Division of Gastroenterology, Casa Sollievo Sofferenza Hospital, IRCCS, San
Giovanni Rotondo, Italy
9Gastroenterology Unit of Comacchio/Lagosanto, Ferrara, Italy
10Gastroenterology Unit, University Campus Bio-Medico of Rome, Rome, Italy
11Digestive Motility Diseases, Department of Clinical Medicine and Surgery, Federico
II University Hospital, Naples, Italy
12Gastroenterology Unit, S. Martino Hospital, Belluno, Italy
13Gastroenterology Unit, Department of Clinical Science, "L. Sacco" University
Hospital, Milan, Italy
14Department of Medicine and Aging Sciences and CESI, G. D’Annunzio University
and Foundation, Chieti, Italy
15Gastroenterology Unit, St. Andrea Hospital, Vercelli, Italy
16Department of Digestive Diseases, Hepatology and Clinical Nutrition, Dell’Angelo
Hospital, Venice, Italy
17Division of Gastroenterology, AO San Camillo Forlanini, Rome, Italy
18Gastroenterology and Digestive Endoscopy Unit, IRCCS Policlinico San Donato, San
Donato Milanese, Italy
19Santissima Annunziata Hospital, Cento, Italy
Acknowledgements We are grateful to Gabriella Bartesaghi from SOFAR S.p.A
and to Daniela Garavaglia and Aldo Poli from OPIS for their constant support in all
phases of the study and assistance in the preparation of the manuscript. We would
like to acknowledge the contribution of the following study participants during the
trial: Angelo Andriulli, Rosanna Cogliandro, Lara Bellacosa, Giovanni Carini, Maria
Raffaella Barbaro.
Contributors GB, CC, RC and VS planned the study, designed the protocol,
contributed to the writing of the manuscript and to the screening and periodic visits
of the patients. VA, GB, FB, MB, AB, LB, FB, PB, MC, RC, BG, MLS, PM, MN, MR,
AS, MLS, MV and GZ contributed to the screening and periodic visits of the
patients. All authors have access to the study data and have reviewed and approved
the ﬁnal manuscript.
Funding This study was supported by Sofar S.p.A., Trezzano Rosa, Milan, Italy.
The funding agency had no role in the study design, collection, analysis, data
interpretation or writing of the report.
Competing interests GB has been a consultant, served on the advisory board,
received speaker’s bureau fees, honorarium and travel support to meetings related to
this study from the study sponsor, and has received consultancy fees and/or speaker fees
from Danone, Yakult, Ironwood, Malesci, Nestlè, Noos, Synergy, Alfa Wassermann,
Almirall and Shire. CC received research funding and travel support to meetings from the
study sponsor. VA has been a consultant/speaker, served on the advisory board or
received research grants fromG iuliani, Abbvie, MS&D, Ferring, Takeda, Nycomed, Shire,
Cosmo Pharmaceuticals, Sofar, SEDA, Hospira, Otsuka, Astra Zeneca, Dicofarm, Alfa
Wassermann, Johnson & Johnson. FB has received research funding, travel support to
meetings and speaker fees from Alfa Wasserman, Aptalis, Astra Zeneca, Sofar. MR
received travel support to meetings from the study sponsor. VS has received consultancy
fees and/or speaker fees from Alfa Wassermann, Almirall, Angelini Aptalis, CM&D
Pharma, Farmaderma, Ironwood, Italchimici, Janssen, Norgine, Shire, Takeda, Valeas,
Vibrant and Zeria. The remaining authors disclose no conﬂicts.
Patient consent Obtained.
Ethics approval The protocol was approved by an independent ethics committee
at each centre and carried out according to the Declaration of Helsinki and the
principles of good clinical practice.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders.
Gastroenterology 2006;130:1480–91.
2 Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med
2013;368:578–9.
3 Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel
syndrome. J Neurogastroenterol Motil 2011;17:349–59.
4 Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology
2009;136:1979–88.
5 Cremon C, Stanghellini V, Pallotti F, et al. Salmonella gastroenteritis during
childhood is a risk factor for irritable bowel syndrome in adulthood.
Gastroenterology 2014;147:69–77.
6 Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon
of patients with irritable bowel syndrome: involvement of soluble mediators.
Gut 2009;58:196–201.
7 Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron
activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol
2011;106:1290–8.
8 Foley S, Garsed K, Singh G, et al. Impaired uptake of serotonin by platelets from
patients with irritable bowel syndrome correlates with duodenal immune activation.
Gastroenterology 2011;140:1434–43 e1.
9 Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of
visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology
2007;132:26–37.
10 Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral
pain in irritable bowel syndrome. J Clin Invest 2007;117:636–47.
11 Buhner S, Li Q, Berger T, et al. Submucous rather than myenteric neurons are
activated by mucosal biopsy supernatants from irritable bowel syndrome patients.
Neurogastroenterol Motil 2012;24:1134–e572.
12 Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by
supernatants of colonic biopsy specimens from patients with irritable bowel
syndrome. Gastroenterology 2009;137:1425–34.
13 Balestra B, Vicini R, Cremon C, et al. Colonic mucosal mediators from patients with
irritable bowel syndrome excite enteric cholinergic motor neurons.
Neurogastroenterol Motil 2012;24:1118–e570.
14 Zucchelli M, Camilleri M, Andreasson AN, et al. Association of TNFSF15
polymorphism with irritable bowel syndrome. Gut 2011;60:1671–7.
15 Swan C, Duroudier NP, Campbell E, et al. Identifying and testing candidate genetic
polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and
TNFalpha. Gut 2013;62:985–94.
16 Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic
mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut
2008;57:468–73.
17 Vivinus-Nebot M, Dainese R, Anty R, et al. Combination of allergic factors can
worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
Am J Gastroenterol 2012;107:75–81.
18 Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel
disorders: a Rome foundation report. Gut 2013;62:159–76.
19 Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal
immune biomarkers in irritable bowel syndrome: a randomized controlled
proof-of-concept study. Aliment Pharmacol Ther 2009;30:245–52.
20 Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled
trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol
Ther 2003;18:77–84.
21 Barbara G, Stanghellini V, Cremon C, et al. Aminosalicylates and other
anti-inﬂammatory compounds for irritable bowel syndrome. Dig Dis 2009;27(Suppl
1):115–21.
22 Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases
visceral hypersensitivity and improves intestinal symptoms in patients with irritable
bowel syndrome. Gut 2010;59:1213–21.
23 Mowat C, Cole A, Windsor A, et al. Guidelines for the management of
inﬂammatory bowel disease in adults. Gut 2011;60:571–607.
24 Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable
bowel syndrome: development and validation of a new measure. Dig Dis Sci
1998;43:400–11.
25 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey
(SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
26 Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional
gastrointestinal disorders. Gastroenterology 2006;130:1538–51.
Barbara G, et al. Gut 2016;65:82–90. doi:10.1136/gutjnl-2014-308188 89
Neurogastroenterology
group.bmj.com on July 19, 2016 - Published by http://gut.bmj.com/Downloaded from 
27 Camilleri M, Northcutt AR, Kong S, et al. Efﬁcacy and safety of alosetron in women
with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet
2000;355:1035–40.
28 Tack J, Muller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the
efﬁcacy and safety of repeated tegaserod therapy in women with irritable bowel
syndrome with constipation. Gut 2005;54:1707–13.
29 Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor
partial agonist, relieves symptoms in irritable bowel syndrome patients with
abdominal pain, bloating and constipation. Aliment Pharmacol Ther
2001;15:1655–66.
30 Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an
understanding of severity. Clin Gastroenterol Hepatol 2005;3:717–25.
31 Spiegel B, Bolus R, Harris LA, et al. Measuring irritable bowel syndrome
patient-reported outcomes with an abdominal pain numeric rating scale. Aliment
Pharmacol Ther 2009;30:1159–70.
32 Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we
use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol
Motil 2013;25:453–7.
33 Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in
irritable bowel syndrome: gender-dependence and association with digestive
symptoms. Am J Gastroenterol 2009;104:392–400.
34 Enck P, Bingel U, Schedlowski M, et al. The placebo response in medicine:
minimize, maximize or personalize? Nat Rev Drug Discov 2013;12:191–204.
35 Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for
chronic constipation. N Engl J Med 2011;365:527–36.
36 Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to
colonic nerves correlate with abdominal pain in irritable bowel syndrome.
Gastroenterology 2004;126:693–702.
37 Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission
in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544.
90 Barbara G, et al. Gut 2016;65:82–90. doi:10.1136/gutjnl-2014-308188
Neurogastroenterology
group.bmj.com on July 19, 2016 - Published by http://gut.bmj.com/Downloaded from 
IBS
Randomised controlled trial of mesalazine in
Vincenzo Stanghellini
Scribano, Maurizio Vecchi, Giorgio Zoli, Roberto Corinaldesi and
Paola Molteni, Matteo Neri, Marcello Rodi, Alfredo Saggioro, Maria Lia 
Paola Buldrini, Michele Cicala, Rosario Cuomo, Bastianello Germanà,
Bazzoli, Massimo Bellini, Antonio Benedetti, Luigi Benini, Fabrizio Bossa, 
Giovanni Barbara, Cesare Cremon, Vito Annese, Guido Basilisco, Franco
doi: 10.1136/gutjnl-2014-308188
2016 65: 82-90 originally published online December 22, 2014Gut 
 http://gut.bmj.com/content/65/1/82
Updated information and services can be found at: 
These include:
Material
Supplementary
 html
http://gut.bmj.com/content/suppl/2014/12/22/gutjnl-2014-308188.DC1.
Supplementary material can be found at: 
References
 #BIBLhttp://gut.bmj.com/content/65/1/82
This article cites 37 articles, 8 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (278)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 19, 2016 - Published by http://gut.bmj.com/Downloaded from 
